Barchart Demo Center

Overview

Stocks

Stock Screeners

ETFs

Futures

Funds

Fund Screeners

Foreign Exchange

Sectors

News

Financial Calculators

Embedded Widgets

Portfolio

Screener

JSON Feeds

Symbol Overview

United States|Canada
English|French

Trillium Therapeutic

(NASDAQ: TRIL)
Add to Portfolio
+0.06 (+1.63%)
as of 20:00 EST

Last 3.74
Change +0.06 (+1.63%)
Open 3.75
Prev. Close 3.68
Today's Range
3.56
3.88
52wk Range
0.24
4.86
Volume 1,613,900
Avg Volume 3,831,440
Sector SIC-2834 Pharmaceutical Preparations

Perfomance Comparison

Name Today 3-Month 1-Year
TRIL +1.63% +1,115.86% +199.20%
DJIA +0.40% +6.03% +13.35%
S&P 500 +0.47% +8.62% +21.81%

Key Statistics

Annual EPS -1.40
Dividend Yield 0.00%
P/E Ratio N/A
Market Capitalization, $K 96,450
Weighted Alpha +55.30
Standard Deviation +0.20
Profit Margin N/A
Beta 2.84

Growth Rates

YTD +263.11%
1-Year +404.11%
3-Year -37.63%
5-Year -75.02%
10-Year -96.12%

Opinion

Sell Hold Buy

Recent Headlines

Trillium Therapeutics Announces Changes to Its Board

GlobeNewswire via COMTEX - Fri Feb 07, 07:00AM EST
Trillium Therapeutics Inc. ("Trillium" or the "Company") (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that Paul Walker has been appointed(full story)
TRIL: 3.74 (+0.06)

Trillium Closes US$117 Million Public Offering of

GlobeNewswire via COMTEX - Wed Jan 29, 07:00AM EST
Trillium Therapeutics Inc. ("Trillium" or the "Company") (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced the closing of its previously annou(full story)
TRIL: 3.74 (+0.06)

Trillium Announces Pricing of US$101,700,000 Public

GlobeNewswire via COMTEX - Thu Jan 23, 08:15AM EST
Trillium Therapeutics Inc. ("Trillium" or the "Company") (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has priced its previously a(full story)
TRIL: 3.74 (+0.06)

Trillium Announces Proposed Public Offering of Common

GlobeNewswire via COMTEX - Wed Jan 22, 04:01PM EST
Trillium Therapeutics Inc. ("Trillium" or the "Company") (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has commenced a public offe(full story)
TRIL: 3.74 (+0.06)

Trillium Therapeutics Regains Compliance With Nasdaq

GlobeNewswire via COMTEX - Thu Jan 16, 08:00AM EST
Trillium Therapeutics Inc. ("Trillium" or the "Company") (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that the Company has regained compl(full story)
TRIL: 3.74 (+0.06)